A. Kamphorst and R. Ahmed, Manipulating the PD-1 pathway to improve immunity, Current Opinion in Immunology, vol.25, issue.3, pp.381-389, 2013.
DOI : 10.1016/j.coi.2013.03.003

J. Riley, PD-1 signaling in primary T cells, Immunological Reviews, vol.5, issue.1, pp.114-139, 2009.
DOI : 10.1111/j.1600-065X.2009.00767.x

H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo, Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor, Immunity, vol.11, issue.2, pp.141-51, 1999.
DOI : 10.1016/S1074-7613(00)80089-8

M. Keir, M. Butte, G. Freeman, and A. Sharpe, PD-1 and Its Ligands in Tolerance and Immunity, Annual Review of Immunology, vol.26, issue.1, pp.677-704, 2008.
DOI : 10.1146/annurev.immunol.26.021607.090331

K. Sheppard, L. Fitz, J. Lee, C. Benander, J. George et al., PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3?? signalosome and downstream signaling to PKC??, FEBS Letters, vol.4, issue.1-3, pp.37-41, 2004.
DOI : 10.1016/j.febslet.2004.07.083

H. Dong, S. Strome, D. Salomao, H. Tamura, F. Hirano et al., Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, vol.8, pp.793-800, 2002.

L. Zitvogel and G. Kroemer, Targeting PD-1/PD-L1 interactions for cancer immunotherapy, OncoImmunology, vol.8, issue.8
DOI : 10.1016/j.coi.2011.12.009

M. Ahmadzadeh, L. Johnson, B. Heemskerk, J. Wunderlich, M. Dudley et al., Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, vol.114, issue.8, pp.1537-1581, 2009.
DOI : 10.1182/blood-2008-12-195792

A. Gros, P. Robbins, X. Yao, Y. Li, S. Turcotte et al., PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors, Journal of Clinical Investigation, vol.124, issue.5, pp.2246-59, 2014.
DOI : 10.1172/JCI73639DS1

O. Hamid, C. Robert, A. Daud, F. Hodi, W. Hwu et al., Safety and Tumor Responses with Lambrolizumab (Anti???PD-1) in Melanoma, New England Journal of Medicine, vol.369, issue.2, pp.134-178, 2013.
DOI : 10.1056/NEJMoa1305133

J. Taube, A. Klein, J. Brahmer, H. Xu, X. Pan et al., Association of PD-1, p.1

N. Rizvi, M. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, issue.6230, pp.124-132, 2015.
DOI : 10.1126/science.aaa1348

N. Labarriere, A. Fortun, A. Bellec, A. Khammari, B. Dreno et al., A Full GMP Process to Select and Amplify Epitope-Specific T Lymphocytes for Adoptive Immunotherapy of Metastatic Melanoma, Clinical and Developmental Immunology, vol.164, issue.2, p.932318, 2013.
DOI : 10.1097/00008390-200209000-00011

Y. Kawakami, S. Eliyahu, C. Delgado, P. Robbins, L. Rivoltini et al., Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor., Proceedings of the National Academy of Sciences, vol.91, issue.9, pp.3515-3524, 1994.
DOI : 10.1073/pnas.91.9.3515

Y. Godet, A. Moreau-aubry, Y. Guilloux, V. Vignard, A. Khammari et al., MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency, The Journal of Experimental Medicine, vol.6, issue.11, pp.2673-82, 2008.
DOI : 10.1038/76292

B. Youngblood, A. Noto, F. Porichis, R. Akondy, Z. Ndhlovu et al., Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells, The Journal of Immunology, vol.191, issue.2, pp.540-544, 2013.
DOI : 10.4049/jimmunol.1203161

B. Youngblood, K. Oestreich, S. Ha, J. Duraiswamy, R. Akondy et al., Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells, Immunity, vol.35, issue.3, pp.400-412, 2011.
DOI : 10.1016/j.immuni.2011.06.015

R. Bouquie, A. Bonnin, K. Bernardeau, A. Khammari, B. Dreno et al., A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes, Cancer Immunology, Immunotherapy, vol.320, issue.4, pp.553-66, 2009.
DOI : 10.1007/s00262-008-0578-2

G. Martinez, R. Pereira, T. Aijo, E. Kim, F. Marangoni et al., The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 T Cells NFATc1 regulates PD-1 expression upon T cell activation, Immunity J Immunol, vol.27, issue.181, pp.4832-4841, 2008.

P. Odorizzi, K. Pauken, M. Paley, A. Sharpe, and E. Wherry, Genetic absence of PD-1

C. Blank, I. Brown, R. Marks, H. Nishimura, T. Honjo et al., Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells, The Journal of Immunology, vol.171, issue.9, pp.4574-81, 2003.
DOI : 10.4049/jimmunol.171.9.4574

H. Nishimura, T. Honjo, and N. Minato, Facilitation of ?? Selection and Modification of Positive Selection in the Thymus of Pd-1???Deficient Mice, The Journal of Experimental Medicine, vol.10, issue.5, pp.891-899, 2000.
DOI : 10.1016/S1074-7613(00)80502-6

R. Wong, R. Scotland, R. Lau, C. Wang, A. Korman et al., Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs, International Immunology, vol.19, issue.10, pp.1223-1257, 2007.
DOI : 10.1093/intimm/dxm091

. High-avidity-melanoma-reactive-cytotoxic, France) (C) IFN-? production of PD-1 neg and PD-1 pos T cell clones in response to melanoma cell lines. IFN-? production was measured by ELISA (n=2) in supernatants of PD-1 neg (left column, dotted lines) and PD-1 pos (right column, solid lines) T cell clones after 6h of activation with M113 melanoma cell line (white circles) or, 2015.